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a b s t r a c t
This study determined the cytotoxic, cyto-selective and mutagenic potential of novel quinolinone Schiff
base ligands and their corresponding copper(II) complexes in human-derived hepatic carcinoma cells
(Hep-G2) and non-malignant human-derived hepatic cells (Chang). Results indicated that complexation
of quinolinone Schiff bases with copper served to significantly enhance cytotoxicity. Here, the complex
of (7E)-7-(3-ethoxy-2-hydroxybenzylideamino)-4-methylquinolin-2(1H)-one (TV117-FM) exhibited
the lowest IC50 value (17.9 mM) following 96 h continuous exposure, which was comparable to
cisplatin (15.0 mM). However, results revealed that TV117-FM lacked cytoselectivity over non-
malignant cells. Additionally, the complex was minimally effluxed from cells via Pglycoprotein (P-gp)
and was shown to be non-mutagenic in the Standard Ames test. Furthermore, BrdU incorporation
assays showed that it was capable of inhibiting DNA synthesis in a concentrationand time-dependent
manner. However, inhibition was not as a consequence of DNA intercalation, as illustrated in
electrophoretic mobility shift assays. Interestingly, it was shown that the ligand was capable of
inhibiting the action of topoisomerase II, but this was lost following complexation. This indicated that
the mechanism of action of the novel copper(II) complex was different from that of the parent ligand
and suggests that TV117-FM may have a therapeutic role to play in the treatment of hepatocellular
carcinoma. Studies are currently underway to elucidate the exact in vitro mechanism of action of this
novel, metal-based anti-cancer agent.
& 2012 Published by Elsevier B.V.
1. Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related death worldwide with particularly high incidences in East
Asia and sub-Saharan Africa (Venook et al., 2010). In Ireland, 180
people are diagnosed annually with HCC, (Irish Cancer Society,
2011). HCC is considered to be a highly malignant disease, with an
extremely poor prognosis, and chronic infections with both
hepatitis B and C viruses (HBV and HCV) are known to be
important risk factors in its development. It has also been linked
to initial chronic hepatitis without direct liver cirrhosis. In
addition, researchers have suggested that HCV, aflatoxin, alcohol
and non-alcoholic fatty liver disease (NAFLD) may either act
independently or interact with HBV to induce liver cirrhosis
(El-Serag and Rudolph, 2007). Also, generation of reactive oxygen
species (ROS) via mitochondrial dysfunction, coupled with down-
regulation of oxido-reductive enzymes have also been linked to
hepatocarcinogenesis (Marra et al., 2011). Moreover, it has been
shown that patients’ origin along with aetiological factors of HCC
development may impact on the type of mutations encountered
in this disease. Colombino et al. (2012) reported a correlation
between mutational activation of the BRAF and PIK3CA genes, and
the tumourigenesis of HCC, in Southern Italy. These genes play
key roles in both cellular proliferation and survival. Therefore,
control of these factors may limit the progression of this disease.
Treatment of the disease is dependent upon the extent of liver
dysfunction or cirrhosis. In early stage HCC, treatment may
involve resection, transplantation or local ablation using trans-
catheter arterial chemoembolisation (TACE), while intermediate
stage HCC is generally treated with TACE and/or yttrium-90
radioembolisation. However, sub-optimal efficacy of these treat-
ments remains a challenge which needs to be addressed (Wo¨rns
and Galle, 2010). Recently, the tyrosine protein kinase inhibitor,
sorafenib has been approved for the treatment of advanced stage
HCC (Keating and Santoro, 2009). In addition, sorafenib, adminis-
tered in combination with octreotide-LAR (long-acting release), a
somatostatin analogue, has been shown to be active and well
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tolerated in the treatment of advanced HCC (Caraglia et al., 2011;
Marra et al., 2011).
Quinolinones are a class of heterocyclic compounds known to
possess diverse therapeutic activities. They act as the structural
backbone of many medicinal drugs in the treatment of a range of
diseases including; inflammatory diseases, psychosis and cancer
(Burris et al., 2002; Kulakarni et al., 2006). However, interest in the
use of quinolinones as anti-cancer agents arose from the finding that
vesnarinone, a quinolinone analogue, used in the treatment of
congestive heart failure, was capable of attenuating the growth of
cancer cells, both in vitro and in vivo (Sato et al., 1995, 1996; Nio
et al., 1997; Kawai et al., 1998). More recently, a novel class of
quinoline-2-ones were shown to be potent photochemotherapeutic
agents with IC50 values at the submicromolar level (Barraja et al.,
2010, 2011). Furthermore, quinolinone derivatives have been
reported to possess pro-apoptotic characteristics (Claassen et al.,
2009). Additionally, Schiff base ligands and their Cu(II) complexes
have shown enhanced anti-cancer activity (Zhao et al., 2007). More-
over, our research group have previously reported the in vitro anti-
fungal potential of novel copper(II) complexes of coumarin-derived
Schiff bases, which are structurally similar to quinolinones (Creaven
et al., 2009) in addition to elucidating the anti-cancer potential of
novel copper-, silver- and manganese-phenantholine (phen) and
phendione complexes (Deegan et al., 2006, 2007). Also, the function
of preventing de novo replication of DNA by topoisomerase II
(TopoII) inhibition is a desirable characteristic of any novel che-
motherapeutic agent, and coumarin-based complexes have also been
shown to be potent TopoII inhibitors (Finn et al., 2004). It is
hypothesised that these novel compounds and their corresponding
Cu(II) complexes may act in a manner similar to that of the copper
complexes of phen and phendione (Deegan et al., 2006). Presently,
the anti-cancer potential of such quinolinone Schiff base copper
complexes, has yet been reported in the literature.
The aim of the current study was to evaluate the in vitro
cytotoxic potential of a series of novel quinolinone Schiff bases
and their corresponding copper(II) complexes, using a hepatocel-
lular carcinoma model cell line, Hep-G2. Subsequently, the cyto-
selective, mutagenic, and TopoII inhibitory potential of the most
potent assessed agent(s) was determined. Where possible, com-
parative studies were carried out with one of the most clinically
used anti-cancer agents, cisplatin. This served to highlight the
clinical potential of members of this series of compounds.
2. Materials and methods
2.1. Test compounds and reagents
Cisplatin, copper perchlorate and actinomycin D were purchased
from Sigma-Aldrich, Ireland. All quinolinone-derived Schiff bases
and corresponding Cu(II) complexes were synthesised and purified
as described by Creaven et al. (2010). Structure and purity were
confirmed by thin layer chromatography, infra red analysis, 1H- and
13C-NMR spectroscopy, along with elemental analysis. Assessed
agents were solubilised in dimethyl sulfoxide (DMSO, 0.25%, v/v).
pGEM-3Z plasmid DNA was purchased from Promega and BrdU cell
proliferation kits were obtained from Calbiochem, U.K. Topoisome-
rase II relaxation kits were purchased from Inspiralis, U.K. All other
chemicals, reagents and growth media were purchased from Sigma-
Aldrich, Ireland, unless otherwise stated.
2.2. Model cell lines
Hep-G2 (human hepatocellular carcinoma) and Chang (non-
neoplastic human hepatic, with possible HeLa contamination)
cells were purchased from the American Type Culture Collection,
Manassas, USA. These cells were maintained in Eagle’s Minimum
Essential Medium (EMEM) with Earle’s Balanced Salt Solution,
containing 1.5 g/l sodium bicarbonate, 2 mM L-glutamine, 0.1 mM
non-essential amino acids, 1 mM sodium pyruvate, 100 U/ml peni-
cillin, 100 mg/ml streptomycin and 10% (v/v) foetal bovine serum.
Chinese hamster ovary cells (CHO-K1 and CHC5) were kindly
provided by Dr. V. Ling, Ontario, Canada. CHO-K1 cells were
maintained in Ham’s F-12 media, containing 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin and 10% (v/v) foetal
bovine serum. CHC5 cells were maintained in EMEM, alpha mod-
ification (without ribonucleosides and deoxynucleosides), contain-
ing 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin
and 10% (v/v) foetal bovine serum. All cell lines were grown at 37 1C
in a humidified atmosphere and in the presence of 5% CO2.
2.3. Assessment of anti-proliferative activity using MTT assay
All quinolinone-derived Schiff bases and their corresponding
Cu(II) complexes were dissolved in DMSO, diluted in culture
media and used to treat model cell lines over a range of drug
concentrations for periods of 4, 24 and 96 h. The maximum
percentage of DMSO present in any well was 0.25% (v/v). Cells
were seeded into sterile 96-well flat-bottomed plates (Sarstedt) at
a density of 2.5104 cells/ml and grown in 5% (v/v) CO2 at 37 1C.
A miniaturised viability assay using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) was carried out
according to the method described by Mosmann (1983). In
metabolically active cells, MTT is reduced by the mitochondrial
enzyme succinate dehydrogenase to form insoluble formazan
crystals that are subsequently solubilised, and the optical density
(OD) measured spectrophotometrically. This method is com-
monly used to illustrate inhibition of cellular proliferation.
Drug-treated cells were assayed by addition of 20 ml of 5 mg/ml
MTT in 0.1 M phosphate buffered saline (PBS), pH 7.4. Following
incubation for 4 h at 37 1C, the overlying medium was aspirated
with a syringe and 100 ml of DMSO was added to dissolve the
formazan crystals. Plates were agitated to ensure complete dis-
solution of crystals and OD was measured at 550 nm using a
Tecan Sunrise microtitre plate reader. Viability was expressed as a
percentage of solvent-treated control cells. This assay had five
replicates per concentration point, and each experiment was
carried out on at least the separate occasions. The IC50 was
calculated for each assessed agent and defined as the concentra-
tion (mM) causing a 50% reduction in cellular proliferation.
2.4. Plate incorporation mutagenicity assay
The possible genotoxicity of assessed agents was investigated
using the Standard Ames bacterial mutation assay described by
Maron and Ames (1983). The primary tester strains used were
Salmonella typhimurium strains TA98 and TA100 (Trinova, Germany),
which detect mutation by frame-shift and base-pair substitution,
respectively. Both strains carry the ampicillin resistance plasmid
pKM101. Tester strains were cultured in Oxoid nutrient broth No. 2
(Fannin, Ireland) to a cell density of 1109 cells/ml (OD of 0.60 at
605 nm) and maintained on minimal glucose plates, supplemented
with 0.5 mM histidine/biotin and ampicillin.
To carry out the Ames test, top agar [0.3% (w/v) agar and 0.5%
(w/v) NaCl] was supplemented with 10 ml of 0.5 mM histidine/
biotin per 100 ml of agar, immediately prior to use. A 2 ml aliquot
of top agar was distributed into a sterile universal tube. A
mammalian enzyme activation system was also included, which
consisted of the S9 liver fraction of a male Sprague–Dawley rat,
induced with aroclor 1254. A 500 ml aliquot of S9 mixture (10%, v/v),
100 ml of assessed agent at the appropriate concentration dissolved
in 0.1 M PBS, pH 7.4, and 100 ml of tester strain were added to 2 ml
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aliquots of molten top agar, mixed and quickly poured over the
surface of minimal glucose plates lacking histidine/biotin. All plates
were then allowed to solidify, inverted and then incubated and
protected from light, at 37 1C for 72 h. Following incubation, the
number of revertant colonies per plate was determined. Each
assessed agent concentration was analysed in triplicate, both in
the presence and absence of the S9 enzyme activation system.
Negative control plates used consisted of tester strain and S9 mix
alone, while the solvent-treated control consisted of tester strain, S9
mixture and solvent vehicle (no assessed agent). This approach
allowed identification and quantification of spontaneous bacterial
revertants. Positive controls included the known mutagens, 4-nitro-
quinoline-N-oxide (NQNO) for TA98 (1–1000 ng/plate) and sodium
azide (0.5–10 mg/plate) for TA100. The metabolising activity of the
rat liver S9 was tested in both strains using 2-aminoanthacene, a
mutagen requiring metabolic activation in order to induce mutation.
2.5. DNA binding studies
The ability of the compounds to bind to DNA by intercalation
was investigated using the electrophoretic mobility shift assay
described by Lorico and Long (1993). Drug binding reactions were
carried out in a final volume of 10 ml containing 5 ml of 50 mM Tris–
HCl, pH 7.5 or assessed agent diluted in 50 mM Tris–HCl, pH 7.5 at
two-fold concentration and 5 ml pGEM-3Z plasmid DNA (Promega)
at a concentration of 0.05 mg/ml. Reactions were carried out at 37 1C
for 2 h and then terminated by the addition of 2.5 ml of termination
buffer [50% (v/v) glycerol; 20 mM EDTA; 0.25% (w/v) bromophenol
blue]. Reactions were immediately electrophoresed on a 1% (w/v)
agarose gel containing ethidium bromide (5 mg/ml) in TAE [40 mM
Tris-acetate pH 8.5; 1 mM EDTA]. DNA bands were visualised by
irradiation at 300 nm and photographed using a Syngene G-Box
imaging system. Doxorubicin (25 mM) was used as positive control,
while the negative control consisted of pGEM-3Z plasmid DNA
incubated with 50 mM Tris–HCl, pH 7.5.
2.6. DNA synthesis studies
The effect of assessed agent on DNA synthesis was determined
using the 5-bromo-2-deoxyuridine (BrdU) colourimetric incorpora-
tion assay (Calbiochem, U.K.). This assay is based on the incorpora-
tion of the halogenated pyrimidine analogue BrdU, into the DNA of
proliferating cells and represents a non-radioactive alternative to the
[3H]-thymidine incorporation assay (Portsmann et al., 1985). BrdU
incorporated into cellular DNA was detected by immunoassay. Cell
lines were seeded at a density of 2.5104 cells/ml into a 96 well
plate in a final volume of 100 ml/well and allowed to adhere
overnight at 37 1C in a humid atmosphere, with 95% air and 5%
CO2. Assessed agent was prepared as described in Section The test
compounds and reagents. A 100 ml aliquot of each assessed agent
concentration was added to 3 replicate wells. The experimental
controls consisted of two negative controls; (i) vehicle-treated cells
and (ii) untreated control cells and the positive control (iii) actino-
mycin-D treated cells. Plates were incubated with assessed agent for
4, 24, and 96 h at 37 1C in a humid atmosphere with 95% air and 5%
CO2. BrdU label (10 mM) was added to each well and the plate
incubated for a further 4 h at 37 1C. Incorporation was quantified
using ELISA (Calbiochem, U.K.).
2.7. DNA topoisomerase II strand-passing assay
pGEM-3Z plasmid DNA was used to measure the strand-passing
ability of topoisomerase II in the presence of assessed agent.
Reactions were carried out in a final volume of 20 ml. These
consisted of the following; 2 ml of topoisomerase II buffer
[100 mM Tris–HCl; pH 7.9; 500 mM NaCl; 500 mM KCl; 500 mM
MgCl2; 1 mM EDTA; 150 mg/ml BSA and 10 mM ATP], 3 ml of pGEM-
3Z plasmid DNA (0.1 mg/ml), 2 units of topoisomerase II [(1 unit/ml)
in 10 mM sodium phosphate, pH 7.1] containing; [(50 mM NaCl,
0.2 mM DTT, 0.1 mM EDTA, 0.5 mg/ml BSA and 10% (v/v) glycerol]
(Inspiralis, UK), 3 ml deionised H2O and 10 ml of assessed agent in
water at a two-fold excess concentration. Reactions were mixed
gently, incubated at 30 1C for 30 min and protected from light.
Topoisomerase reactions were terminated by the addition of 3 ml of
7 mM EDTA, containing 0.77% (w/v) SDS. Experimental controls
consisted of pGEM-3Z plasmid DNA alone, topoisomerase II and
pGEM-3Z plasmid DNA, topoisomerase II, pGEM-3Z plasmid DNA
and the topoisomerase II inhibitor, novobiocin (10 mM) (Sigma).
Finally, 4.6 ml of 6 X tracking dye [0.05% (w/v) bromophenol blue
and 50% (v/v) glycerol] was added to each reaction tube. This was
applied to 1% (w/v) agarose gels and electrophoresed in TAE buffer
[40 mM Tris-acetate pH 8.5; 1 mM EDTA] for 2.5 h at 80 V. Gels
were stained in ethidium bromide (5 mg/ml), destained in deionised
H2O, visualised and photographed by irradiation at 300 nm using a
Syngene G-Box imaging system.
2.8. Statistical analyses
Statistical analyses were performed using the software pack-
age SigmaStatTM 8.0. Statistical analysis of solvent-treated cells
compared with cells treated with test agent was evaluated using
one-way ANOVA (Analysis Of Variance). A probability of 0.05 or
less was deemed statistically significant. The standard error of the
mean (S.E.M.) was estimated for all values. The following notation
was used throughout; nPo0.05, nnPo0.01.
3. Results
3.1. Anti-proliferative and cyto-selective properties
The dose-dependent anti-proliferative effect of quinolinone
Schiff bases and their copper complexes was assessed using Hep-
G2 cells and the MTT bioassay. The MTT assay was carried out as
described in Section The assessment of anti-proliferative activity
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Fig. 1. Anti-proliferative effect of quinolinone Schiff bases on Hep-G2 cells, as
assessed by MTT. Results presented represent anti-proliferative assays carried out
in 96 well plates with continuous exposure to assessed agent (0–1000 mM) for
96 h. All assessed agents except TV117-E caused a dose-dependent decrease in
cellular proliferation. Results obtained were expressed as a percentage of solvent-
treated control cells. Bars indicate mean7S.E.M., n¼3.
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using MTT assay . Cells were continuously exposed to assessed
agent for 96 h, and their effect on cellular proliferation deter-
mined. Dose-response curves of cell viability versus assessed
agent concentration were used to calculate the IC50 value for
each assessed agent (Figs. 1 and 2, Table 1).
Results obtained indicated that all assessed agents, with the
exception of copper perchlorate and TV117-E, caused a concen-
tration-dependent decrease in cellular proliferation in Hep-G2
cells (Fig. 1). The most potent quinolinone Schiff base observed
was TV117-G, with an IC50 value of 175.7 mM. When quinolinone
Schiff bases were complexed with copper, the anti-cancer poten-
tial of all compounds was significantly increased (Fig. 2 and
Table 1). Interestingly, TV117-F possessed an IC50 value of
398.3 mM but its copper complex, TV117-FM exhibited an IC50
value of 17.9 mM. Moreover, TV117-FM was shown to be the
compound with the greatest anti-proliferative activity in this
series. Therefore, selected aspects of the mechanism of action of
TV117-FM were studied.
Comparative studies were carried out using one of the most
widely used Pt-based drugs, cisplatin. The cytotoxicity of cisplatin
in Hep-G2 cells was previously determined (Deegan et al., 2006).
Cisplatin demonstrated an IC50 value of 15.0 mM in Hep-G2 cells at
96 h (Table 1). Therefore, the anti-cancer activity seen with
cisplatin was comparable to that observed with TV117-FM.
As TV117-FM was shown to be the most cytotoxic agent
screened in this series, it was decided to carry out a time-course
study on its cytotoxicity. For comparative purposes, the ligand,
the complex and the metal salt (copper perchlorate), were
included in this experiment, incubated with Hep-G2 cells for 4,
24 and 96 h, and their effect on cellular viability determined.
Results presented in Table 2 clearly indicated that the anti-
proliferative activity of TV117-FM increased with time, unlike
that seen with the ligand, TV117-F or copper perchlorate. Addi-
tionally, the effect of TV117-FM on cellular viability is presented
in Fig. 3, where it was evident that the anti-proliferative activity
was both time- and concentration-dependent.
In order to determine the possible cyto-selective nature of
TV117-FM, a matched non-malignant hepatic cell line, Chang was
used, as previously described in Section The model cell lines .
TV117-FM exhibited a similar trend in its cytotoxicity across both
cell lines after 96 h incubation, with an IC50 value of 17.9 mM in
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Fig. 2. Anti-proliferative effect of quinolinone Schiff base copper complexes on
Hep-G2 cells, as assessed by MTT. Results presented represent anti-proliferative
assays carried out in 96 well plates with continuous exposure to assessed agent
(0–200 mM) for 96 h. All assessed agents, except copper perchlorate, caused a
dose-dependent decrease in cellular proliferation, with TV117-FM exhibiting the
greatest potency. Results obtained were expressed as a percentage of solvent-
treated control cells. Bars indicate mean7S.E.M., n¼3.
Table 1
Anti-proliferative effect of quinolinone Schiff bases and their corresponding copper complexes (denoted, M) in Hep-G2 cells following 96 h
continuous incubation with assessed agent in the range 0–1000 mM, using MTT assay. A graph of viability (% of solvent-treated control cells) versus
concentration was used to calculate the IC50 values (mM). Results presented are representative of thee independent experiments (Mean7S.E.M.,
n¼3). (4 , greater than).
Hep-G2
Compound Abbreviation IC50 (lM)7S.E.M.
(7E)-7-(2hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one TV117-C 411.677.3
(7E)-7-(2,3dihydroxybenzylideneamino)-4-methylquinolin-2(1H)-one TV117-E 41000
(7E)-7-(3-ethoxy-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one TV117-F 398.3733.2
(7E)-7-(2-hydroxy-3-methoxybenzylideneamino)-4-methylquinolin-2(1H)-one TV117-G 175.7712.2
(7E)-7-(2-hydroxy-4-methoxybenzylideneamino)-4-methylquinolin-2(1H)-one TV117-H 521.774.7
[Cu(aL)2]-CM TV117-CM 74.878.9
b
[Cu(aL)2]-EM TV117-EM 129.0716.3
b
[Cu(aL)2]-FM TV117-FM 17.973.8
b
[Cu(aL)2]-GM TV117-GM 105.3725.4
b
[Cu(aL)2]-HM TV117-HM 53.271.6
b
Copper perchlorate CuClO4 4200
cis-diamminedichloroplatinum(II) Cisplatin 15.072.6
a L denotes ligand.
b Po0.01 statistically different from IC50 value of parent ligand).
Table 2
Anti-proliferative effect of TV117-F, its copper complex TV117-FM and copper
perchlorate in Hep-G2 cells following 4, 24, and 96 h continuous incubation with
assessed agent in the range 0–200 mM, using MTT assay. A graph of viability (% of
solvent-treated control cells) versus concentration was used to calculate the IC50
values (mM). Results presented are representative of thee independent experi-
ments (Mean7S.E.M., n¼3). (4 , greater than).
Hep-G2 IC50 (lM)7S.E.M.
Compound 4 h 24 h 96 h
TV117-F 4200 4200 4200
TV117-FM 68.0712.4 26.573.3 17.973.8
Copper perchlorate 4200 4200 4200
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Hep-G2 cells and an IC50 value of 15.3 mM in Chang cells (Fig. 4).
These data suggested that TV117-FM was cytotoxic to both cell
lines and did not offer cyto-selectivity, in the model used.
To determine whether TV117-FM was a potential substrate for
P-gp-mediated MDR, both CHC5 and CHO-K1 cells were incubated
for 96 h with a range of concentrations of assessed agent.
Subsequently, the IC50 was determined by MTT assay and used
to calculate resistance factors (Rf) for both cell lines (Table 3).
Vinblastine, a known P-gp substrate exhibited lower anti-prolif-
erative activity in CHC5 cells than in CHO-K1 cells, due to its
efflux from CHC5 cells via P-gp. Rf’s were calculated to determine
the fold-difference in concentration of assessed agent, required to
elicit the same effect (IC50) in the CHC5 cells than in the CHO-K1
cells. The Rf for vinblastine was 47.5. Therefore, an assessed agent
with an Rf equal to or greater than 47.5 suggested that they were
likely to be effluxed from cells in a manner similar to that seen
with the known P-gp substrate, vinblastine. However, TV117-FM
possessed an Rf of 3.2, which was a factor of 15 lower than that
seen with vinblastine. Thus, TV117-FM was less likely to be a
substrate for P-gp-mediated MDR, than vinblastine.
3.2. Mutagenic potential of assessed agents
The Standard Ames test was employed in order to establish the
mutagenic potential of TV117-F, TV117-FM and copper perchlo-
rate, along with their phase I metabolites. Positive controls
consisting of nitro-quinoline-N-oxide (NQNO) for TA98 and
sodium azide (NaN3) for TA100 were included in all experiments
(data not shown). Furthermore, the activity of the S9 fraction was
validated with the inclusion of 2-aminoanthacene, which requires
metabolic activation prior to producing a positive mutagenic
response in the Ames test (data not shown).
The results presented in Figs. 5 and 6 indicated that none of
the assessed agents along with their phase I metabolites, caused
mutation by either frame-shift or base-pair substitution, as no
concentration-dependent fold-increase in revertant colonies was
apparent. Furthermore, each assessed agent was screened at
concentrations over four orders of magnitude, in an effort to
visualise any possible mutagenic effect. Therefore, using the
Standard Ames test neither the ligand, its copper complex nor
copper perchlorate met the criteria, and so cannot be considered
mutagenic.
3.3. Determination of the intercalative nature of TV117-FM
The ability of assessed agents to intercalate DNA, thus con-
tributing to decreased cell viability, was elucidated using gel
mobility shift assays. Plasmid DNA was incubated with assessed
agent over a range of concentrations equivalent to the IC25, IC50
and IC75 (as determined using Hep-G2 cells following 96 h) and
DNA was subsequently separated using agarose gel electrophor-
esis. Doxorubicin, a known DNA intercalator was used as a
positive control (25 mM). The results obtained (Fig. 7) clearly
indicated that regardless of concentration used (9–30 mM) TV117-
FM did not intercalate DNA, as it did not alter the migration
pattern of either open circular (OC) or supercoiled (SC) conforma-
tions of plasmid DNA, unlike the positive control, doxorubicin.
3.4. Inhibition of DNA synthesis
In an attempt to determine the effect of assessed agents on
DNA synthesis, BrdU incorporation assays were carried out,
according to the method described by Portsmann et al. (1985).
These assays were carried out in Hep-G2 cells following 4, 24 and
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Fig. 3. Anti-proliferative effect of TV117-FM on Hep-G2 cells over time, as
assessed by MTT. Results presented represent anti-proliferative assays carried
out in 96 well plates with continuous exposure to assessed agent (0–200 mM) for
4, 24 or 96 h. TV117-FM caused both a concentration- and time-dependent
dependent decrease in cellular proliferation. Results obtained were expressed as
a percentage of solvent-treated control cells. Bars indicate mean7S.E.M., n¼3.
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Fig. 4. Anti-proliferative effect of TV117-FM on Hep-G2 and Chang cells following
96 h treatment, as assessed by MTT. Results presented represent anti-proliferative
assays carried out in 96 well plates with continuous exposure to assessed agent
(0–200 mM) for 96 h. TV117-FM exhibited similar cytotoxicity trends between the
hepatic cell carcinoma-derived Hep-G2 cells and the Chang cells (derived from
normal liver tissue). IC50 values were found to be 17.9 and 15.3 mM in Hep-G2 and
Chang cells, respectively. Results obtained were expressed as a percentage of
solvent-treated control cells. Bars indicate mean7S.E.M., n¼3.
Table 3
Anti-proliferative effect of TV117-FM in P-gp deficient CHO-K1 cells and P-gp
over-expressing CHC5 cells following 96 h continuous incubation with assessed
agent, using MTT assay. The resistance factor (Rf) was calculated using vinblastine,
a known P-gp substrate. Rf for assessed agents were also calculated and compared
to that of vinblastine to demonstrate whether assessed agents were substrates for
P-gp. Results presented are representative of thee independent experiments
(Mean7S.E.M., n¼3).
IC50 (lM)7S.E.M.
Compound CHO-K1 CHRC5 Rf
Vinblastine 0.0170.005 0.47570.10 47.5
TV117-FM 16.9071.02 54.67710.17 3.2
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96 h incubation with assessed agent. Additionally, actinomycin D
was included in experiments as a positive control (Fig. 8B).
TV117-FM exhibited both a time- and concentration-dependent
decrease in DNA synthesis by 96 h and at high concentrations,
caused a complete inhibition of DNA synthesis (Fig. 8A). More-
over, this response was similar to that of actinomycin D (Fig. 8B).
3.5. Inhibition of topoisomerase II
Quinolinones have been shown to inhibit prokaryotic DNA
cleavage via inhibition of topoisomerase IV and DNA gyrase
(Wang et al., 2008). The eukaryotic homolog of topoisomerase IV
is topoisomerase II. Therefore, the ability of each assessed agent to
inhibit topoisomerase II mediated relaxation of pGEM-3Z plasmid
DNA was determined (see Section DNA topoisomerase II strand-
passing assay). Electrophoretic analysis (Fig. 9) demonstrated that
there was a low proportion of OC together with a higher proportion
of SC DNA in the control sample, which did not contain enzyme or
inhibitor (Fig. 9, lane 2). Incubation of pGEM-3Z DNA with topoi-
somerase II resulted in the formation of a significant proportion of
relaxed DNA bands and a reduction in the bands representative of
OC and SC DNA (Fig. 9, lane 3). The positive control novobiocin
(10 mM) inhibited the activity of topoisomerase II (Fig. 9, lane 4),
while TV117-F (200 mM) was capable of inhibiting topoisomerase II
activity (Fig. 9, lane 9) in a manner similar to that seen with the
positive control (Fig. 9, lane 4). However, none of the other assessed
agents, and at any of the concentrations used, displayed comparable
inhibition of TopoII activity (Fig. 9, lanes 5–8, lane 10).
4. Discussion
The aim of the present study was to determine the in vitro
cytotoxic potential of novel quinolinone Schiff base ligands and
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Fig. 5. Effect of TV117-F, its copper complex TV117-FM and copper perchlorate on S. typhimurium strain TA98 in the (A) absence and (B) presence of a mammalian
metabolic activation system (S9). Results presented represent Standard Ames assay carried out following 72 h continuous exposure of TA98 to assessed agent. Results
obtained were expressed as a fold increase in revertant colonies relative to control. Bars indicate mean7S.E.M., n¼3.
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their copper(II) complexes, along with elucidating the cyto-
selective, mutagenic and TopoII inhibitory potential of the most
potent assessed agent(s). Presently, treatment for HCC may
involve surgical resection, transplantation, TACE or radioemboli-
sation with the treatment modality dependent upon staging of
the disease (Wo¨rns and Galle, 2010). More recently, the use of
targeted therapies, such as the tyrosine kinase inhibitor sorafenib,
and the somatostatin analogue octreotide, have proved to be
promising in the treatment of advanced stage HCC, both singly
and in combination (Del Prete et al., 2010; Caraglia et al., 2011;
Marra et al., 2011). In addition, Caraglia and co-workers (2011)Q3
reported a gradual decrease in ROS production and ERK1/2
activation in patients responsive to treatment with sorafenib plus
octreotide, over a 21-day period. These authors suggested that
ROS and activated ERK1/2 status in peripheral blood mononuclear
cells may be used as predictors of response to treatment with
such targeted agents.
It has previously been shown that transition metal complexes
of Schiff base ligands can improve the anti-microbial and anti-
cancer activities of the ligand (Holla et al., 2008). More specifi-
cally, several Schiff bases ligands and their copper(II) complexes
have enhanced anti-neoplastic activity (Zhao et al., 2007; Barraja
et al., 2010, 2011). Our research group has previously described
the potent anti-cancer activity and the in vitro mechanisms of
action of a series of innovative copper-, silver- and manganese-
complexes of phen and phendione ligands (Deegan et al., 2006,
2007).
Here anti-proliferative assays using MTT were carried out to
determine IC50 values for each quinolinone Schiff base and their
corresponding copper(II) complexes in Hep-G2 cells following
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Fig. 6. Effect of TV117-F, its copper complex TV117-FM and copper perchlorate on S. typhimurium strain TA100 in the (A) absence and (B) presence of a mammalian
metabolic activation system (S9). Results presented represent Standard Ames assay carried out following 48 h continuous exposure of TA100 to assessed agent. Results
obtained were expressed a as fold increase in revertant colonies compared to control. Bars indicate mean7S.E.M., n¼3.
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96 h incubation. The copper salt; copper perchlorate (CuClO4) was
also included in assays in order to determine if inhibition in cellular
viability was caused by the ligand, the complex or the simple salt
alone. Moreover, results obtained were compared to the anti-
proliferative effect of cisplatin seen previously, in this cell line
(Deegan et al., 2006). These assays showed that following 96 h
incubation, quinolinone Schiff bases exhibited relatively poor anti-
proliferative effects (Table 1; Fig. 1). However, cytotoxicity was
enhanced in all corresponding copper complexes (Table 1; Fig. 2).
Additionally, CuClO4 proved to be inactive as an independent anti-
cancer agent. Therefore, the anti-proliferative effect seen was
significantly enhanced by complexation of the quinolinone Schiff
bases to copper. The compound exhibiting the greatest cytotoxicity
was TV117-FM. Moreover, this complex displayed an anti-neoplastic
profile similar to that seen with cisplatin.
Subsequently, the time-dependent anti-cancer activity of
TV117-FM, its parent ligand; TV117-F and the copper salt; CuClO4
was determined. TV117-FM displayed both a concentration- and
time-dependent decrease in cellular proliferation (Table 2; Fig. 3)
which was in contrast to that seen for TV117-F and CuClO4.
Moreover, TV117-FM exhibited a greater anti-proliferative effect
4 h post-treatment compared to the Schiff bases studied. In
addition, following 96 h incubation of Hep-G2 cells with TV117-
FM, a near-complete inhibition of metabolic activity was observed
at concentrations greater than 50 mM (Fig. 3). Therefore, TV117-
FM appeared to be a potent, fast-acting, novel anti-cancer agent,
compared to its parent ligand or indeed any ligand screened in
the series.
An extremely rare attribute of anti-cancer agents is their
ability to naturally select and inhibit the growth of neoplastic
over non-neoplastic cells. Thus, to ascertain whether TV117-FM
possessed such a trait, its cyto-selective nature was determined
using Chang cells. These cells were thought to be derived from
normal hepatic tissue, therefore, they are a commonly used match
to assess the cyto-selectivity of agents already screened with
Hep-G2 cells (Deegan et al., 2006, 2007). However, it should be
noted that Chang cells have known HeLa cell contamination,
therefore any potential data obtained indicating cyto-selectivity
towards these model cells should be confirmed by screening
using primary human hepatocytes. Results presented in Fig. 4
suggested that TV117-FM was incapable of selecting malignant
over non-malignant targets, in a trend dissimilar to that seen
previously with cisplatin (Deegan et al., 2006). However, as many
potent therapeutics are incapable of displaying cyto-selectivity, it
was decided to further evaluate the anti-cancer activity of this
novel agent.
In order to ensure that the anti-proliferative effect seen with
TV117-FM was not attenuated by P-gp mediated MDR, a cellular
model for MDR-1 was used. Comparison of the anti-proliferative
data from the CHO-K1 and CHC5 cells indicated that TV117-FM
was not a likely substrate for P-gp compared to the known P-gp
substrate, vinblastine (Table 3). Furthermore, TV117-FM was
shown to be 15 times less likely to be effluxed from a P-gp
abundant cell relative to vinblastine. Thus, it is unlikely that
TV117-FM is a substrate for P-gp mediated MDR and therefore
remains within cells where its cytotoxic potential may ensue.
Additionally, it is desirable that novel anti-cancer agents are
non-mutagenic, as it would be unfavourable to administer a
chemotherapeutic compound which in itself may cause muta-
tions. For this reason, our assessed agents were analysed using
the Standard Ames test to determine their mutagenic potential.
The results obtained (Figs. 5 and 6) showed that TV117-F, TV117-
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FM and CuClO4 did not cause a significant dose-dependent
increase in the number of revertant colonies, regardless of tester
strain used, and the presence or absence of the S9 enzyme
activation system. This suggested that these agents and their
phase I metabolites were non-mutagenic. These results compare
favourably with other copper complexes previously examined by
our group using the Standard Ames test (Deegan et al., 2006,
2007). Here, copper-phendione and copper-phen complexes,
along with their phase I metabolites were shown to be non-
mutagenic. Thus, the current findings indicated that if TV117-FM
was used clinically, its application would not be limited by its
potential mutagenicity, unlike that seen with cisplatin (Hannan
et al., 1989; Cross et al., 1996). From their studies they high-
lighted the possible risk of secondary malignancies in patients
undergoing treatment with cisplatin.
In an effort to determine if TV117-FM inhibited DNA synthesis
directly by targeting the DNA molecule, in a manner analogous to
cisplatin, electrophoretic mobility shift assays were employed.
Results presented in Fig. 7 confirmed that, regardless of the
concentration used, TV117-FM did not intercalate DNA, unlike
the positive control, doxorubicin. Therefore, TV117-FM ultimately
inhibited DNA synthesis although it was by a mechanism other
than intercalation and the exact mechanism remains to be
determined.
Having established that TV117-FM did not intercalate DNA, we
next sought to examine its effect on DNA synthesis, using BrdU
incorporation assays. The results obtained suggested that TV117-
FM exhibited significant inhibitory effect which was both time-
and concentration-dependent, in a trend similar to that seen with
the positive control, actinomycin D. Furthermore, these results
are consistent with those seen by Deegan et al. (2006, 2007).
These researchers reported a concentration-dependent inhibition
of DNA synthesis in Hep-G2 cells by copper-phendione and
copper-phen agents.
The prevention of de novo replication of DNA via topoisome-
rase II inhibition is a desirable characteristic of any novel
chemotherapeutic agent (Larsen et al., 2003). Additionally, many
quinolinone-, quinoline- and coumarin-based compounds have
been shown to be potent topoisomerase II inhibitors (Bredberg
et al., 1991; Corbett et al., 1993; Q2Lorico and Long, 1993; Finn et al.,
2004). Therefore, it was decided to examine the effect of TV117-
FM, its quinolinone ligand, TV117-F and CuClO4 on the inhibition
of topoisomerase II activity. These experiments were conducted
using a cell-free system (see Section DNA topoisomerase II strand-
passing assay). Results presented in Fig. 9 indicated that TV117-F
was the only assessed agent capable of inhibiting topoisomerase
II activity and in a manner similar to the positive control,
novobiocin. This result indicated that when TV117-F was com-
plexed with copper, its ability to interact with topoisomerase II
was diminished. Additionally, TV117-FM caused a dose-depen-
dent decrease in DNA synthesis, although, this effect was not
mediated though DNA intercalation (Fig. 7). Therefore, from the
data presented here, it was clear that the presence of a copper
moiety in the quinolinone Schiff base structure somehow pre-
vented inhibition of topoisomerase II. However, the exact
mechanism(s) underlying this process remains to be elucidated.
In conclusion, the in vitro cytotoxic, cyto-selective and muta-
genic potential of a series of novel quinolinone Schiff base ligands
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85
87
89
91
93
95
97
99
101
103
105
107
109
111
113
115
119
121
123
125
127
129
131
133
0
20
40
60
80
100
120
Conc. (μM)
B
rd
U
 in
co
rp
or
at
io
n 
as
 %
 o
f c
on
tro
l
4 h
24 h
96 h
0
20
40
60
80
100
120
2 10 25 50 100 125 150 200
4 40 400 4000
Conc. (nM)
B
rd
U
 in
co
rp
or
at
io
n 
as
%
 o
f c
on
tro
l
4 h
24 h
96 h
Fig. 8. Effect of (A) TV117-FM and (B) Actinomycin D on DNA synthesis in Hep-G2 cells, as assessed by BrdU incorporation. Results presented represent BrdU incorporation
assays carried out in 96 well plates with continuous exposure to assessed agents (0–200 mM) for 4, 24 and 96 h. (A) TV117-FM and (B) Actinomycin D caused a time- and
dose-dependent decrease in DNA synthesis. Results obtained were expressed as BrdU incorporation as a percentage of solvent-treated control cells. Bars indicate
mean7S.E.M., n¼3. *Po0.05 **Po0.01.
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and corresponding Cu(II) complexes have been studied. The most
potent Cu complex was TV117-FM, an agent unlikely to be
effluxed from cells via P-gp, dissimilar to many chemotherapeutic
agents. Furthermore, it inhibited DNA synthesis in a concentra-
tion- and time-dependent manner, but not though intercalation
or inhibition of topoisomerase II. Taken together, the work
presented here culminated in identification of a potent anti-
cancer agent, with a cytotoxic profile similar to the clinically
used anti-cancer drug, cisplatin. Future studies will focus on
identifying the possible pro-apoptotic mechanisms underlying
the anti-proliferative effects of TV117-FM. Additionally, it is
intended that proteomic studies may allow identification of key
cellular targets and in doing so, assist in elucidating their
mechanisms of action, thus facilitating the development of an
effective anti-cancer agent for the treatment of HCC.
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